• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinical application of prognostic markers for pancreatic cancer to predict postoperative prognosis at the preoperative stage

Research Project

Project/Area Number 20K07699
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionKochi University

Principal Investigator

Ogasawara Mitsunari  高知大学, 教育研究部医療学系臨床医学部門, 助教 (10605215)

Co-Investigator(Kenkyū-buntansha) 谷内 恵介  高知大学, 教育研究部医療学系臨床医学部門, 准教授 (50626869)
Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords膵癌 / 予後予測マーカー / 予後予測因子 / 術前化学療法 / バイオマーカー
Outline of Research at the Start

膵癌細胞の浸潤・転移に関わるRUVBL1とPRDX1を同定した。手術前に採取された膵癌生検組織を免疫組織染色することにより、RUVBL1とPRDX1の予後解析を行う臨床試験を実施している。1年生存率の予後解析を終了し、RUVBL1とPRDX1の両方が高発現している症例では臨床ステージ分類に基づく予測よりも高い精度で手術前の段階で術後予後を正確に予測できた。本研究では、①臨床試験を継続して実施して2022年度に予後解析を終了する、②RUVBL1とPRDX1をノックダウンしたヒト膵癌細胞株をマウス膵臓に移植したモデルマウスを用いてRUVBL1とPRDX1がマウスの予後に関わることを示す。

Outline of Final Research Achievements

Through our own basic research, we identified RUVBL1 and PRDX1 associated with the invasiveness and metastasis of pancreatic cancer cells. Currently, we are conducting a retrospective clinical study for prognostic analysis of RUVBL1 and PRDX1 by immunohistochemical staining using 25 pancreatic cancer tissue samples preoperatively obtained by the fine-needle aspiration biopsy. In this study, (1) we completed the prognostic analysis of the retrospective study in 2022, and (2) we completed mouse experiments using human pancreatic cancer cell lines with knockdown of RUVBL1 and PRDX1.
This clinical study showed that the group with high expression of both RUVBL1 and PRDX1 had a significantly worse prognosis than the low expression group. In a basic study using a mouse model, the prognosis of mice transplanted with human pancreatic cancer cell line PANC-1 cells, in which the expression of RUVBL1 and PRDX1 was suppressed, showed a longer prognosis than that of the control group.

Academic Significance and Societal Importance of the Research Achievements

全身状態、CA19-9、肝転移、腹膜播種などが膵癌の予後予測因子として報告されている。しかし、これらの論文報告では、臨床病期との比較が詳細に行われていない。膵癌患者の予後を手術前に高い精度で予測できる方法を定めることができれば、特にステージIIAまでの切除可能膵癌において術前治療の適応基準を決めることが臨床の現場の重要課題であり、本研究の成果が術前化学療法を必要とする患者を絞り込むことに貢献できる可能性がある。本研究は、臨床病期だけでは不十分な予後予測を補完することのできる世界初のバイオマーカー同定を目指しており、臨床のニーズに合致した研究を推進できると考えている。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (8 results)

All 2022 2021 2020 2019

All Journal Article (4 results) (of which Peer Reviewed: 4 results,  Open Access: 3 results) Presentation (1 results) (of which Invited: 1 results) Patent(Industrial Property Rights) (3 results) (of which Overseas: 1 results)

  • [Journal Article] Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2-013-derived organoid.2022

    • Author(s)
      Tanaka C, Furihata K, Naganuma S, Ogasawara M, Yoshioka R, Taniguchi H, Furihata M, Taniuchi K
    • Journal Title

      Human cell.

      Volume: 35(2) Issue: 2 Pages: 735-744

    • DOI

      10.1007/s13577-022-00684-7

    • Related Report
      2022 Annual Research Report 2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients.2022

    • Author(s)
      Taniuchi K, Ueno M, Yokose T, Sakaguchi M, Yoshioka R, Ogasawara M, Kosaki T, Naganuma S, Furihata M
    • Journal Title

      PLoS One.

      Volume: 17(3) Issue: 3 Pages: e0265172-e0265172

    • DOI

      10.1371/journal.pone.0265172

    • Related Report
      2022 Annual Research Report 2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Measurement of PODXL and SCGB1D2 for detecting intraductal papillary mucinous neoplasm2021

    • Author(s)
      谷内 恵介、岡林 雄大、阪口 昌彦、岩田 純
    • Journal Title

      Nippon Shokakibyo Gakkai Zasshi

      Volume: 118 Issue: 3 Pages: 235-244

    • DOI

      10.11405/nisshoshi.118.235

    • NAID

      130007996133

    • ISSN
      0446-6586, 1349-7693
    • Year and Date
      2021-03-10
    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] KHSRP-bound small nucleolar RNAs associate with promotion of cell invasiveness and metastasis of pancreatic cancer.2019

    • Author(s)
      Taniuchi K, Ogasawara M.
    • Journal Title

      Oncotarget

      Volume: 11 Issue: 2 Pages: 131-147

    • DOI

      10.18632/oncotarget.27413

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 新規治療薬の承認を目指した膵癌研究.2020

    • Author(s)
      谷内恵介
    • Organizer
      第38回日本ヒト細胞学会総会
    • Related Report
      2020 Research-status Report
    • Invited
  • [Patent(Industrial Property Rights)] 膵がん及び膵管内乳頭粘液性腫瘍のマーカー2021

    • Inventor(s)
      谷内恵介
    • Industrial Property Rights Holder
      谷内恵介
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-115619
    • Filing Date
      2021
    • Related Report
      2021 Research-status Report
  • [Patent(Industrial Property Rights)] Marker for pancreatic cancer and intraductal papillary mucinous neoplasms2021

    • Inventor(s)
      谷内恵介
    • Industrial Property Rights Holder
      谷内恵介
    • Industrial Property Rights Type
      特許
    • Filing Date
      2021
    • Acquisition Date
      2021
    • Related Report
      2021 Research-status Report
    • Overseas
  • [Patent(Industrial Property Rights)] 膵がん診断キット2020

    • Inventor(s)
      谷内恵介
    • Industrial Property Rights Holder
      高知大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2020-174333
    • Filing Date
      2020
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi